相关实验视频

Updated: Jun 14, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

在患有严重喘的患者中从其他生物药物转换为tzepelumab:一项回顾性研究

Toshiyuki Sumi¹, Taiki Ishigooka¹, Keigo Matsuura¹

¹Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, 38-3 Goryoukaku-Cho, Hakodate, Hokkaido, 040-8611, Japan; Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan.

Respiratory investigation

|May 8, 2025

概括

切换为tzepelumab (抗胸腺性 stromal lymphopoietin抗体) 改善了先前用其他生物药物治疗的患者的严重喘控制. 许多患者经历了恶化的减少和改善的肺功能,表明tezepelumabb.

科学领域:

肺部医学肺部医学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

严重的喘 (SA) 是一个重大挑战,特别是在2型 (T2) 炎症较低的患者中.
泰泽佩卢马布是一种胸膜 stromal lymphopoietin (TSLP) 抑制剂,已在管理SA方面表现出有效性.
以前的生物药物可能无法充分控制SA,需要替代治疗策略.

研究的目的:

评估在SA患者中切换到tzepelumab的疗效和安全性,这些患者在之前的生物治疗中控制不充分.
评估临床结果,包括喘控制,口服皮质类固醇 (OCS) 使用,肺功能和恶化率.

主要方法:

对22名SA患者的回顾性分析,这些患者在24周或更长时间内转换为tezepelumab (210毫克每4周一次).
评估喘控制测试 (ACT) 评分,OCS剂量,1秒内强制呼吸量 (FEV1) 和恶化频率的变化.
生物标志物评估包括外周血液中的乙氨基基,IgE和呼出的氧化 (FeNO).

主要成果:

77%的患者在12周后没有恶化;64%的患者获得了临床显著的ACT得分增加 (≥3).
18%的患者实现了喘缓解 (ACT ≥23,没有恶化,无类固醇).
在ACT得分,FEV1 (+40毫升) 和OCS剂量中观察到显著改善;根据先前的生物治疗,反应有所不同.

结论:

采佩卢马布显示出作为对其他生物药物耐药的SA患者有效治疗的潜力.
需要进一步的研究来确认长期的结果,并确定最佳的患者选择标准,以治疗tzepelumab.

关键词:

喘控制测试 (ACT) 是一种测试.生物疗法是一种生物疗法.严重的喘严重的喘泰泽佩卢姆巴布 (Tezepelumab) 是一个小镇.这是一种2型炎症.

更多相关视频

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

相关概念视频

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Asthma-IV: Diagnostic and Management

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...